Welgus Howard G. sold $114K of ARQT

Welgus Howard G. sold 4,730 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $24.18 ($0.11M total) on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Welgus Howard G.
Published Sep 17, 2026, 8:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARQT
Neutral
medium confidence
Mentioned
$ARQT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQTNeutralLow
01

Why it matters

The sale adds marginal selling pressure; investors may monitor future insider activity for signals.

02

Market read

Small insider sale with limited trading relevance; primarily informational.

03

What to watch

Potential upcoming clinical trial milestones that may affect insider sentiment.

Relevance 3/10Novelty 4/10Timing: post‑market 2026-09-15

Background

Form 4 filings disclose insider transactions; a director's sale under a pre‑arranged 10b5‑1 plan is a standard disclosure.

Company-level read

Ticker impact

$ARQTNeutralMedium confidence
Context

Director Welgus Howard G. sold 4,730 shares of ARQT for $114,371 on 2026-09-15 via a 10b5‑1 plan.

Expected impact

Limited short‑term downside risk; unlikely to move price materially.

Evidence & confidence

A $114k sale by a director represents a minor ownership change; market typically discounts such small insider sales.

Market effects

Minimal impact on biotech sector; insider sales are routine.

None

None

Counterpoint

If the director is reducing exposure, it could signal concerns about upcoming data, but the size is too small to infer.

Key entities

  • Arcutis Biotherapeutics, Inc.

    Biotech firm developing dermatology therapies, ticker ARQT.

  • Welgus Howard G.

    Director of ARQT who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARQTHighAI 8/10

Arcutis reports trial data on infant eczema treatment candidate

Arcutis Biotherapeutics (ARQT) presented INTEGUMENT-INFANT trial data for ZORYVE cream 0.05% in treating infant atopic dermatitis. The study showed no serious adverse events, with 66.7% of infants reporting itch improvement within 4 hours. The cream is approved for children 2-5 years and is under FDA review for infants 3-24 months, with a decision expected by February 23, 2027.

$ARQTMed

Arcutis (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.

$ARQTMedAI 8/10

TD Cowen raises Arcutis stock price target on Zoryve momentum

TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.